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6Service of Pathology, Hospital of San Bonifacio, Verona, ItalyBackground/Aims:Clinico-pathological manifestations of ferroportin (Fpn) disease (FD) are heterogeneous, with some
patients presenting with iron overload predominantly in macrophages (‘‘M” phenotype), others predominantly in hepato-
cytes (‘‘H” phenotype). This appears to reﬂect functional heterogeneity of Fpn mutants, with loss-of-function generally
resulting in the M type.
Methods:Two unrelated probands with ‘‘non-HFE” hemochromatosis were screened for Fpn mutations. Mutants were
functionally characterized by immunoﬂuorescence microscopy, evaluation of their ability to bind hepcidin and export iron,
and by expressing them in zebraﬁsh.
Results:Two novel Fpn mutations were identiﬁed: I152F in patient-1, presenting with typical M phenotype; and L233P
in patient-2, presenting with ambiguous features (massive overload in both macrophages and hepatocytes). Molecular stud-
ies suggested loss of function in both cases. The I152F, normally localized on cell membrane and internalized by hepcidin,
showed a unique ‘‘primary” deﬁcit of iron export capability. The L233P did not appropriately traﬃc to cell surface. Loss
of function was conﬁrmed by expressing both mutants in vivo in zebraﬁsh, resulting in iron limited erythropoiesis. Clinical
manifestations were likely enhanced in both patients by non-genetic factors (HCV, alcohol).
Conclusions:The combination of careful review of clinico-pathological data with molecular studies can yield compelling
explanations for phenotype heterogeneity in FD.
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Ferroportin (Fpn), a 571 amino acid transmembrane
protein, plays a critical role in iron metabolism. Cells
possess several diﬀerent mechanisms for taking up iron
[1], but Fpn is the only known cellular iron exporter.
Fpn controls iron entry into the plasma through duode-
nal enterocytes (1–2 mg/day) or macrophages that
recycle near 20–30 mg/day of iron from senescentPublished by Elsevier B.V. All rights reserved.
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receptor for hepcidin, a master regulator of iron homeo-
stasis [3]. Binding of hepcidin downregulates Fpn
through induction of its internalization and degradation
[4], the ﬁnal results being a reduction of plasma iron
concentration and an increase of intracellular ferritin.
Missense mutations in the Fpn gene lead to ferroportin
disease (FD), also known as type IV hereditary hemo-
chromatosis (HH). This disorder is emerging as the sec-
ond commonest inherited disorder of iron metabolism
after ‘‘classic” HFE-related HH [5]. FD is relatively
milder than other types of HH [6], although progression
to liver cancer has been recently reported [7]. FD also
diﬀers from all other types of HH because of the domi-
nant transmission, the pathophysiology (involving the
hepcidin target rather than a defect of hepcidin itself),
and the heterogeneous clinical presentation. Diﬀerence
in disease presentation is thought to reﬂect the diﬀerent
functional behaviour of the various mutations. The
most frequent category of mutations result in ‘‘loss-of-
function”, mainly because of retention of the mutant
Fpn into the endoplasmic reticulum leading to inappro-
priately low plasma membrane expression of Fpn. The
decreased surface expression of Fpn leads to iron over-
load predominantly in macrophages (‘‘M” phenotype).
Patients with this disorder present with hyperferritin-
emia, normal to low transferrin saturation (TS), and
possibly transient iron-restricted erythropoiesis, espe-
cially during phlebotomies. The second category of
Fpn mutations includes ‘‘gain-of-function” mutations,
mainly because of resistance to hepcidin-induced degra-
dation. These mutants are associated with high TS and
iron loading in hepatocytes (‘‘H” phenotype). The pre-
sentation of this disorder is clinically indistinguishable
from other types of HH. This classiﬁcation may be an
oversimpliﬁcation that often does not ﬁt with observa-
tions in clinical practice. We describe here two novel
mutations in the Fpn gene occurring in two unrelated? ?
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Fig. 1. Pedigree of two patients. The probands are indicated by arrows. (A)
available.patients, one of them presenting with clinico-pathologi-
cal features of massive iron overload. The functional
role of the two Fpn mutations was studied in mamma-
lian cell culture and zebraﬁsh.2. Materials and methods
2.1. Case description
Both patients were referred to our regional Centre for
Iron Overload Disorders in Verona for evaluation of
‘‘non-HFE” hemochromatosis. The study was approved
by the local Ethical Committee (Azienda Ospedaliera di
Verona). A written informed consent was obtained from
either the patients or their relatives in accordance with
the Declaration of Helsinki.
2.1.1. Case 1
A 59-year-old female came to our observation in
October 2004 because of hyperferritinemia (1916 lg/l)
and a slight increase of aminotransferases (AST 44 U/
l, ALT 79 U/l; normal value <40), found during a family
screening for hemochromatosis. A few months before,
her 34-year-old son was incidentally found to have
hyperferritinemia (900 lg/l, TS not available) (Fig. 1A)
during preliminary evaluation in becoming a blood
donor. The patient was started on a phlebotomy pro-
gram. The patient’s brother was also reported to have
high ferritin levels. At the time of our ﬁrst evaluation,
the patient had already undergone 8 phlebotomies of
about 400 ml each, her serum ferritin was 1771 lg/L,
and TS was 22.7%. A more comprehensive laboratory
investigation revealed the presence of previously unrec-
ognized diabetes mellitus (DM) and positive serology
for hepatitis C virus (HCV). HCV-RNA also resulted
positive. Alcohol intake was negligible. She complained
of arthralgias involving proximal and distal interphalan-? ?
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Patient No. 1; (B) Patient No. 2. Iron parameters are reported when
Fig. 2. Liver histology of patient No. 2 at diagnosis. Massive iron
overload is evident, with large coalescent deposits of hemosiderin
especially in Kupﬀer cells, but also in hepatocytes (grade 4). There was
also grade 1 steatosis, and portal ﬁbrosis without overt cirrhosis.
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mation were present. Other relevant data on physical
examination were overweight (BMI 28 kg/m2), and
hepatomegaly (3 cm below the costal margin). Non-
invasive quantiﬁcation of liver iron content by means
of MRI using the Gandon’s protocol [8] yielded a value
of 150 lmol/g (normal value <36 lmol/g). It was possi-
ble to perform a liver biopsy only after attaining normal
ferritin levels by phlebotomies (total iron removed: 7 g).
The histopathology showed portal and peri-portal lym-
phocytic inﬁltrates consistent with HCV-related chronic
hepatitis, along with septal ﬁbrosis and mild steatosis.
On Pearl’s staining, no signiﬁcant iron was found in
hepatocytes, while rare deposits of hemosiderin were
seen in macrophages (not shown).
2.1.2. Case 2
A 64-year-old man, came to our observation in Sep-
tember 2005. He ﬁrst underwent laboratory investiga-
tions in 2000, at the age of 59 years, because of
hepatomegaly (8 cm below the costal margin) found
during a routine control examination by the family
physician. On this occasion, he was found to have
marked hyperferritinemia (9000 lg/l) and increased
TS (74.8%), along with slight elevation of aminotrans-
ferases (AST 44 U/L; ALT 96 U/L), and hyperglyca-
emia consistent with a previously unrecognized DM.
He underwent a liver biopsy, the ﬁndings of which
were consistent with HH. He was then started on an
intensive phlebotomy program (one 500 ml-U weekly).
During the ﬁrst month he developed a slight asymp-
tomatic anemia (nadir of hemoglobin 12 g/dl). The
phlebotomy program was unchanged, and hemoglobin
levels rapidly rose and stabilized to 14.5–15 g/dl over
the second month. At the time of our evaluation, he
had nearly 300 phlebotomies (at least 75 g iron
removed) throughout the previous four years. A pre-
cise retrospective estimation of iron deposits at diagno-
sis was not possible because of lack of data on serum
ferritin during treatment. He declared a previous alco-
hol intake of about 1 L of wine per week, and one
drink of strong brandy per day until 2000. Until the
age of 50 he had been an occasional blood donor
(total donations: 10 U). There was no family history
of iron overload or liver diseases (both parents were
deceased for unrelated diseases). A biochemical screen-
ing of his 38-year-old son revealed normal serum iron
indices (TS 21.4%, ferritin 174 lg/l) (Fig. 1B). A review
of the original liver biopsy (Fig. 2) showed massive
iron overload with large coalescent deposits of hemo-
siderin especially in Kupﬀer cells, but also in hepato-
cytes (grade 4). There was also grade 1 steatosis, and
portal ﬁbrosis without overt cirrhosis. An abdominal
MRI performed at diagnosis revealed the presence of
iron deposits not only in the liver, but also in the
spleen.2.2. Genetic analyses
Denaturing high-performance liquid chromatogra-
phy (DHPLC) scanning of the hemochromatosis genes
was performed on a WaveTM DNA fragment Analysis
System (Transgenomic), as previously described [9,10].
2.3. Generation of Fpn constructs
All Fpn mutations were generated in pFpn-EGFP-
N1 by using the QuikChange site-directed mutagenesis
kit (Stratagene), ampliﬁed in Escherichia coli, and
sequence-veriﬁed before transfecting into mammalian
cells.
2.4. Cells and media
Mouse Fpn was expressed in a cytomegalovirus
(CMV)-containing vector (pEGFP-N1, Clontech,
Mountain View, CA) as described previously [11].
Human embryonic kidney (HEK) 293T cells were main-
tained in DMEM with 10% fetal bovine serum and
transfected with pFpn-EGFP-N1 and pFpn(muta-
tions)-EGFP-N1, by using Nucleofector technology
(Amaxa, Gaithersburg, MD), according to the manufac-
turer’s directions.
2.5. Ferritin analysis
Cells expressing GFP only, wild-type (wt) Fpn-GFP,
or mutant Fpn-GFP were incubated with 10 lM ferric
ammonium citrate (FAC) for 24 h. After FAC loading,
cells were harvested, and ferritin content was determined
by enzyme-linked immunosorbent assay (ELISA) as
described previously [12].
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Maintenance of zebraﬁsh stocks and embryo cultures
were performed as previously described [13]. Mouse
Fpn-GFP were puriﬁed using the EndoFree puriﬁcation
kit (Qiagen, Chatsworth, CA). Approximately 30–50 pg
DNA was microinjected into zebraﬁsh embryos at the
1-cell stage. Embryos were stained with o-dianisidine
to detect hemoglobinized cells as described [13].
2.7. Urinary hepcidin assay
Urinary hepcidin was measured by SELDI-TOF-MS
as previously described [14]. Relative concentrations of
urinary hepcidin-25 were expressed as Mega Intensity
units per millimole of creatinine (MIU/mM crea).3. Results
3.1. Genetic analyses
The molecular analyses of Fpn gene (SLC40A1)
revealed the presence of two novel missense mutations
(Fig. 3). Patient 1 was found to carry an A758T change
in exon 5 resulting in the substitution of isoleucine with
phenylalanine at position 152 (I152F) (Fig. 3A). Patient
2 was found to carry a T1012C change in exon 6, result-
ing in the substitution of leucine with proline at position
233 (L233P) (Fig. 3B). Scanning of other HH-related
genes showed the presence of heterozygosity for theFig. 3. Sequence analyses of the two novel mutations. (A) the I152F mutation (
type sample.H63D mutation in HFE gene in patient 1, and an intro-
nic polymorphism of TfR2 (IVS15+7C>T) in patient 2.
No variation was found in genes coding for hepcidin
(HAMP) and hemojuvelin (HJV) in either patient.
3.2. Subcellular localization and response to hepcidin of
mutant Fpn
Cultured HEK293T cells were transfected with plas-
mids containing mutant Fpn-GFP under the control of
the CMV promoter, and the cellular distribution of
the expressed protein was examined by ﬂuorescence
microscopy. Wild-type Fpn was localized to the cell sur-
face. After incubation with hepcidin for 24 hours, most
of the wt Fpn was internalized (Fig. 4, column A). The
mutant Fpn-GFP I152F was properly localized on the
cell membrane, but after incubation with hepcidin was
internalized slower than wt Fpn (Fig. 4, column B; Sup-
plemental Fig. 1). On the other hand, Fpn-GFP L233P
showed a mixed localization in either the cytoplasm or
the plasma membrane. Addition of hepcidin led to the
internalization of cell surface Fpn-GFP L233P (Fig. 4,
column C).
3.3. Iron export capability
The ability of mutant Fpns to export iron was evalu-
ated. Cells expressing wt or mutant Fpn were incubated
in high iron (10 lM FAC) containing medium, which
resulted in accumulation of the iron storage protein fer-
ritin. As expected, expression of wt Fpn-GFP decreasedarrowed); (B) the L233P mutation (arrowed); both compared with a wild-
Fig. 4. Functional analyses of the new Fpn mutations and response to hepcidin. HEK293T cells were transiently transfected with plasmids containing Fpn-
GFP wt (A), Fpn-GFP I152F (B), or Fpn-GFP L233P (C), and localization was assessed by epiﬂuorescence microscopy (top panel). Eighteen h after
transfection, cells were incubated with 1 lg/ml hepcidin for 24 h and examined for Fpn-GFP localization (bottom panel).
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Fpn-GFP I152F resulted in a partial retention of ferritin
as compared with wt Fpn-GFP. Since this mutant Fpn
showed correct localization at the cell surface, the defectFig. 5. Fpn mutations aﬀect intracellular ferritin levels. HEK293T cells
were transiently transfected with plasmids containing Fpn-GFP wt or
mutant Fpn-GFP. Cells were cultured with ferric ammonium citrate
(FAC) (10 lM). After FAC loading (24 h), cells were incubated with
1 lg/ml hepcidin (24 h), harvested, and ferritin levels were determined by
ELISA. Error bars refers to three independent experiments.
Fig. 6. Expression of mutant Fpn in zebraﬁsh aﬀects hemoglobinization
of erythrocytes. Zebraﬁsh embryos were injected with wt or mutant Fpn-
GFP. At 72 h post-fertilization the embryos were stained with o-
dianisidine to detect hemoglobinized cells (brown color denoted by the
arrow; A, wild-type Fpn). A severe reduction in hemoglobin production
was observed in embryos expressing both the mutations, especially for the
L233P (B and C). The ﬁgures are representative of three diﬀerent
experiments in which 100 embryos were injected with each construct. The
survival rate was 85% for embryos injected with wild type constructs,
75% for embryos injected with I152F constructs, and 77% for embryos
injected with L233P constructs.
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Cells expressing Fpn-GFP L233P showed substantial
retention of ferritin, suggesting a severe impairment of
iron export capability that could be considered second-
ary to the inappropriate membrane localization of this
mutant.
3.4. Expression of Fpn mutations in zebraﬁsh
We investigated the eﬀect of expression of Fpn
mutants on erythroid development in zebraﬁsh. Expres-
sion of wt Fpn had no eﬀect on the development of
erythrocytes (brown staining, denoted by arrow in
Fig. 6A). On the other hand, a severe reduction in hemo-
globin production was observed in embryos expressing
both the mutations, especially for the L233P (Fig. 6B
and C).
3.5. Urinary hepcidin (u-hepcidin) by SELDI-TOF-MS
Urinary hepcidin level in both patients was below our
reference range in control subjects: 0.14 MIU/mM cre-
atinine in patient 1, and 0.19 MIU/mM creatinine in
patient 2; reference range: 0.31–0.66 MIU/mM creati-
nine [14].4. Discussion
Functional studies of Fpn mutations have been often
reported apart from antecedent clinical descriptions,
making a proper interpretation of clinical/molecular
correlations diﬃcult. A further problem is represented
by the relative paucity of liver biopsies reported [5]. In
this study we performed a comprehensive functional
description of two novel FPN mutations, and used this
data to interpret the clinical phenotype.
4.1. Clinical phenotypes
The clinical presentation of the two index cases was
diﬀerent. Patient 1 presented with dominant hyperferr-
itinemia and normal TS, consistent with a typical ‘‘M
phenotype” associated to loss-of-function mutations.
Patient 2, however, presented with ambiguous features
because of a lack of a demonstrable positive family his-
tory, elevation of both ferritin and TS, and pathological
ﬁndings of massive iron overload in both macrophages
and hepatocytes.
4.2. Functional studies in cellular models
Transfection of mutant Fpn constructs into diﬀerent
cell types has been successfully used to assess their func-
tional behaviour [11]. It permits an evaluation of their
cellular localization, as well as their ability to bind hep-cidin and to export iron. A proper membrane localiza-
tion of Fpn is critical for iron export activity. Most
‘‘loss-of-function” mutations have been shown to result
from defects of Fpn traﬃcking to the cell surface, prob-
ably because of a tendency to aggregate and/or misfold
that leads to entrapment into the endoplasmic reticu-
lum. At the opposite end of the spectrum are ‘‘gain-of-
function” mutants that are properly localized on the
membrane, but are resistant to hepcidin inactivation
[11,15,16]. The new Fpn mutations described here
appear to result in a loss-of-function, though with diﬀer-
ent mechanisms. Fpn I152F showed peculiar behaviour:
it was properly localized on the cell surface and
responded normally to hepcidin. Experiments in iron-
loaded mammalian cells and in zebraﬁsh expressing
the mutant Fpn were consistent with an intrinsic defect
of the iron export capability. Isoleucine at position 152
is part of a highly conserved region, and in alignments
of both mouse and human Fpn proteins is placed at
the border of the IV (out of 12) transmembrane domain
by most prediction models [17]. Our observations sug-
gest that this conserved amino acid may be critical for
proper iron eﬄux. To our knowledge, this is the ﬁrst
report of a transport incompetent Fpn mutant that
localizes properly to the cell membrane. A similar
behaviour was previously reported for the N174I muta-
tion [18], while in that case nearly half of the mutant
protein showed intracellular localization.
The Fpn L233P mutant showed a typical defect in cell
surface localization, which is suﬃcient per se to explain
the inability to export iron. The leucine at position 233 is
predicted to be part of an intracellular segment of the
protein [17], which may result in retaining into the endo-
plasmic reticulum when mutated.
4.3. Expression of the mutations in zebraﬁsh
Zebraﬁsh (Danio rerio) represents an emerging tool as
an animal model for human diseases because of the
unique combination of easy manipulability and optical
clarity of embryos, which allows real-time imaging of
developing pathologies [19], particularly in the ﬁeld of
hematology [20]. Indeed, Fpn itself was originally identi-
ﬁed by positional cloning in the weh zebraﬁsh hypochro-
mic anemia mutant [21]. Expression of Fpn mutants in
zebraﬁsh can identify thoseFpnmutants that lead tomac-
rophage iron retention [13]. The observed anemic pheno-
types (Fig. 6) unequivocally conﬁrmed the assignation of
the two novel mutations to the ‘‘loss-of-function” cate-
gory, resulting in iron-restricted erythropoiesis because
of ineﬃcient iron release from macrophages.
4.4. Recapitulation of clinical and molecular data
While the apparent typical ‘‘M” phenotype observed
in patient 1 is in accordance with molecular data, the
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less obvious to interpret. The loss-of-function behaviour
of the L233P suggests a type ‘‘M” phenotype with late
secondary hepatocyte overload. A number of clinical
considerations are consistent with this view: (1) the
TS, though high, was lower than expected considering
the extreme elevation of serum ferritin and the degree
of iron overload at diagnosis, suggesting a late TS
increase similar to that previously reported by others
[5]; (2) the MRI at diagnosis showed substantial iron
overload of the spleen (rich of macrophages), at vari-
ance with the iron-deprivation macrophage phenotype
that occurs in HFE-related HH, as well as in ‘‘H” vari-
ants of FD [22]; (3) while histopathology examination
showed a massive iron overload, there was a relative
prevalence of iron accumulation in Kupﬀer cells, and
absence of overt cirrhosis as one might expect to be pres-
ent if primary hepatocyte overload had occurred over
several years with ferritin levels consistently higher than
1000 lg/l [23,24]. The relative sparing of lobular archi-
tecture in this patient is also in accordance with the gen-
eral notion that primary Kupﬀer cell iron overload is
better tolerated and less ﬁbrogenic than its parenchymal
counterpart [25].
Despite the ‘‘M” phenotype, both the patients toler-
ated phlebotomies, even if a marginal transient anemia
was observed in patient 2 during the ﬁrst month of
weekly phlebotomies. Thus, phlebotomy is conﬁrmed
as an eﬀective therapeutic tool in most FD patients,
while the development of signs of iron-restricted eryth-
ropoiesis during treatment, when present, remains a clue
suggesting the M form of FD.
We found low urinary hepcidin in both patients.
Until now, only scanty data exist on hepcidin levels
in FD. Papanikolaou et al. [26] reported high levels
in two subjects carrying the Val162del mutation, sub-
sequently placed into the loss-of-function category
[11]. This was attributed to a putative compensatory
loop to hepcidin ‘‘insensitivity”. The hepcidin assay
has been proposed as a useful tool for rapid diﬀeren-
tiation of FD from other types of HH, all character-
ized by hepcidin deﬁciency [27]. Noteworthy, both
our patients were under maintenance phlebotomy at
time of sampling, and their hepcidin levels substan-
tially overlapped with those of phlebotomized HFE-
HH patients [14]. Two opposite forces are expected
to regulate hepcidin in phlebotomized FD patients:
inhibition by stimulated erythropoiesis [3], or induc-
tion related to the attempt to minimize iron overload
and/or to overcome true ‘‘hepcidin resistance”. Our
data suggest that the inhibitory erythropoietic signal
tends to prevail, which is in accordance with observa-
tions in HFE-HH phlebotomized patients and in other
conditions of activated erythropoiesis [28]. Thus, assay
of hepcidin might be useful in diagnosing FD only in
patients evaluated before starting phlebotomy and/orin certain mutants subtypes that show constitutive
hepcidin resistance.
Finally, it is remarkable to note that clinical expres-
sivity in both patients was likely enhanced by the inter-
action of non-genetic factors. Current views consider
HH as the result of complex, non-linear interactions
between genetic and acquired factors. Clinical manifes-
tations are determined not only by the underlying dis-
ease-related mutation(s), but also by coinheritance of
modiﬁer genes, and, particularly, by host-related factors
leading to non-genetic hepcidin inhibition [22]. Among
the latter, long known modiﬁers such as ethanol abuse
and HCV have been recently demonstrated to inhibit
hepcidin transcription/expression [29,30]. In light of this
view, it appears that the relatively high clinical expres-
sivity observed was mediated by the co-presence of
HCV infection (patient 1), and alcohol intake (patient
2).5. Conclusions
This study shows that the combination of functional
studies with careful review of clinico-pathological data
can yield compelling explanations for the heterogeneous
phenotypes observed in FD.
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